NCT07059377RecruitingPhase 3
Semaglutide for Smoking Cessation in Patients With Diabetes
Semaglutide for Smoking Cessation in Patients With Diabetes: A Pilot Randomized Controlled Trial
Source: ClinicalTrials.gov · Last updated 8 Sept 2026
Brief summary (registry, in English)
To assess the feasibility of conducting a randomized controlled trial (RCT) to determine the effectiveness of semaglutide as an adjunct to combination NRT in supporting smoking cessation for patients with diabetes.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- First submitted
- 30 Apr 2025
- Start date
- 13 Feb 2026
- Primary completion date
- Dec 2026
- Lead sponsor
- Ottawa Heart Institute Research Corporation
- Diseases
- Type 2 diabetes
- NCT number
- NCT07059377
What you commit to
- Study type: Interventional · Phase 3
- Planned participants: 100
- From 13 Feb 2026 to the primary completion date, Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Use of a DPP-IV inhibitor within the last 7 days.
Other illness
- Initiation of a new diabetes medication within the last 3 months.
- As per the product monograph, participants with the following diagnoses or disorders will be excluded;
- Personal or family history of medullary thyroid cancer
- Personal or family history of Multiple Endocrine Neoplasia syndrome type 2
- Type I diabetes
- Acute pancreatitis or pancreatic cancer
- Acute, chronic or end-stage renal failure
- Unable to engage in follow-up for any reason (for example an acute mental illness, cognitive impairment, unable to speak English or French).
- Other conditions deemed by the study team to interfere with participation or outcomes in the opinion of the study investigator (for example acutely unwell, life expectancy less than 1 year).
Other
- Pregnant or breastfeeding individuals
- Contraindication to NRT or GLP-1 RA.
- Current daily use of NRT or a GLP1 RA.
- Use of bupropion, cytisine, and varenicline within the last 7 days.
- Diabetic ketoacidosis
- Tachyarrhythmias
Who the study is looking for
- Adults (18 years or older) with type 2 diabetes
- Currently residing in Ontario
- Smoke at least five cigarettes per day and willing to reduce or quit smoking within the next 6 months
- Stable HbA1c ≥7.0% - 10% with no more than a 1% change over the last 3 to 6 months.
- Have not used GLP-1 receptor agonists in the past six months.
- Able to provide informed consent
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Ottawa Heart Institute Coordinator of this site? Confirm its status | Ottawa | Canada | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.